One hundred and fifty six healthy adults with moderate to severe lateral periobital (around the eyes) lines, horizontal forehead lines, and glabellar frown lines (areal between the eyebrows and above the nose).
The study was conducted as a randomized trial with 105 patients being treated with Xeomin (incobotulinumtoxinA), while 51 patients received a placebo. The 105 patients had a mean age of 47.4 years and 80.5% were women. The placebo group had a mean age of 47.5, with 80.4% being women.
The investigator-assessed Merz Aesthetic Scales (MAS) were then measured in each treatment area on the 30th day of the test. Adverse effects were also recorded until day 120 of the study. The study found that Xeomin had a significant effect over the placebo. The statistics included effects with the following outcomes:
The researchers concluded that “incobotulinumtoxinA demonstrated significant efficacy in treating glabellar frown lines, horizontal forehead lines and lateral periobital lines separately and combined.” The study also said, “The effects were maintained up to 120 days, and the treatment was well-tolerated.” Only two cases of mild eyelid ptosis (drooping) occurred with the use of incobotulinumtoxinA.
Dr. Thomas Wright, Medical Director of Laser Lipo and Vein Center, says, “We have found Xeomin to be very effective in treating facial lines. Having our results backed up with a well-researched study can give our patients the knowledge that it can be a proven procedure that does, in fact, produce good results.”
“Additionally, the study proves that Xeomin has a good safety profile,” continues Dr. Wright.
Dr. Wright and his staff at Laser Lipo and Vein Center feel that providing the results patients expect in a safe and comfortable methodology is paramount. This study’s findings provide information that Xeomin does provide highly effective results with few side effects.
If you are interested in reducing the appearance of wrinkles and lines, please contact us at the Laser Lipo and Vein Center to discuss your possible options.
1Source: Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From a Randomized, Double-Blind Placebo-Controlled, Phase III Study